Leadership in Biopharma: a Conversation with John Milligan, CEO of Gilead Sciences and Harold E. "Barry" Selick, Vice Chancellor for Business Development, Innovation and Partnerships of UCSF

Byers Auditorium, Genentech Hall, UCSF Mission Bay
4-5 PM, Thursday, May 11. Reception to follow

Click Here to RSVP

Gilead Sciences is a Bay Area titan, a life science leader known for its pipeline of antivirals and Hepatitis C therapeutics. Its CEO is John F. Milligan, PhD, a former UCSF postdoc, who joined the company in 1990 as its 32nd employee. Join us on May 11 when Barry Selick, Vice Chancellor for Business Development, Innovation and Partnerships at UCSF, will engage Milligan in a conversation touching on topics such as Milligan's career path from postdoc to CEO of a major biotech, his experience leading it, and how Gilead feeds its pipeline of innovation and develops new products. Brook Byers, a Founding Partner of Kleiner Perkins Caufield & Byers and a member of the UCSF Board of Overseers, will provide introductory remarks.

Agenda

4:00 pm Introduction: Brook Byers, Partner, Kleiner Perkins Caufield & Byers

4:00-5:00 pm Remarks from John Milligan, Gilead Sciences, followed by audience Q&A and a conversation moderated by Barry Selick, UCSF

5:00-6:30 pm Reception

This event is hosted by UCSF and QB3.

Speakers

Brook Byers, MBA
Founding Partner
Kleiner Perkins Caufield & Byers
Brook Byers is a Founding Partner of Kleiner Perkins Caufield & Byers. A venture capital investor since 1972, Brook has been closely involved with more than 60 new technology-based ventures, many of which have become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare and biotechnology sectors. KPCB has invested in and helped build more than 170 life
Harold (Barry) Selick, PhD
Vice Chancellor for Business Development, Innovation and Partnerships
UCSF
Harold E. "Barry" Selick, Ph.D. is Vice Chancellor for Business Development, Innovation and Partnerships at UCSF. He also serves as Chairman of Threshold Pharmaceuticals, having led the company as CEO from June 2002 to April 2017. Between June 2002 and July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company that was acquired by
John Milligan, PhD
CEO
Gilead Sciences
John F. Milligan, Ph.D. joined Gilead Sciences in 1990 and was appointed Chief Executive Officer in March 2016. He began his career at Gilead as a research scientist, and subsequently held leadership positions in project management and corporate development before being named Chief Financial Officer in 2002. He was appointed Chief Operating Officer in 2007 and President in 2008. During his tenure at Gilead, Dr. Milligan has led teams that have developed, manufactured and commercialized more